Trial

NC002 Phase II Trial to Evaluate the Efficacy, Safety and Tolerability of the Following: PA-824 Plus Moxifloxacin Plus Pyrazinamide in Drug Sensitive and Multi-Drug Resistant Patients

Study Director
Start Date
3 / 2012
Trial Phase
Trial Status
Current Enrollment
Target Enrollment
230
Overview
Compound Associations
Pretomanid (PA-824) in combination with bedaquiline, moxifloxacin, pyrazinamide, and linezolid